156 results about "Blood vessel disorder" patented technology

A method of treating cardiovascular disease in a medical patient is provided. The method includes the steps of generating a sensor signal indicative of a fluid pressure within the left atrium of the patient's heart, and delivering an electrical stimulus to a location in the heart. The electrical stimulus is delivered based at least in part on the sensor signal. The method also includes the steps of generating a proccessor output indicative of a treatment to a signaling device. The processor output is based at least in part on the sensor signal. At least two treatment signals are provided to the medical patient. The treatment signals are distinguishable from one another by the patient, and are indicative of a therapeutic treatment. The treatment signals are based at least in part on the processor output.

A method of treating cardiovascular disease in a medical patient is provided. The method includes the steps of generating a sensor signal indicative of a fluid pressure within the left atrium of the patient's heart, and delivering an electrical stimulus to a location in the heart. The electrical stimulus is delivered based at least in part on the sensor signal. The method also includes the steps of generating a proccessor output indicative of a treatment to a signaling device. The processor output is based at least in part on the sensor signal. At least two treatment signals are provided to the medical patient. The treatment signals are distinguishable from one another by the patient, and are indicative of a therapeutic treatment. The treatment signals are based at least in part on the processor output.

A system for treating a vascular condition includes a conduit having an inner wall and at least one locking member positioned within the inner wall of the conduit. The system also includes a stented valve positioned in contact with the locking member within the inner wall of the conduit. A method for treating a vascular condition includes inserting a conduit with a stented valve into a target region of a vessel, positioning a contact portion of the stented valve against a locking portion of the conduit and preventing migration of the stented valve within the conduit based on the positioning.

A method and system of performing an intravascular procedure at a treatment site in a vessel of a patient. A device creates a seal to prevent the flow of blood during the treatment of vascular disease. A seal may be formed between the distal inside diameter of a sheath or catheter such as a guide catheter as well as within a vessel, such as an artery or vein. An elongated device having a distal portion extending from the catheter and having a fluid impermeable membrane disposed about at least the distal end of the device is used to seal the vessel. The system includes a device to occlude blood flow and a distal protection device to filter or remove embolic debris.

A vascular interventional device may be introduced over a guidewire into a vessel of the cardiovascular system of a patient. This device includes a hollow, flexible tube having a proximal end and a distal end that is adapted to selectively engage a target vessel of the cardiovascular system of the patient. This tube also includes a lumen that is continuous from the proximal to the distal end, and has an end hole in the distal end that is in fluid communication with the lumen. The device also includes a hollow vessel dilator that is adapted for insertion into and through the tube and over the guidewire. The dilator has an inside diameter that is slightly larger than the guidewire and an outside diameter that is slightly smaller than the diameter of the lumen of the tube. The distal end of the dilator is adapted to accommodate vascular entry over the guidewire, and the dilator is adapted to dilate the vessel to accept the tube. The device also includes a hub at the proximal end of the tube. The hub includes an end port through which a second interventional device having an outside diameter smaller than the diameter of the lumen may be introduced into the lumen of the tube. The hub also includes a side port through which a fluid agent may be injected for delivery through the lumen and out the end hole of the tube. A sealing mechanism is also provided in the hub to prevent air from entering the tube and blood and other fluids from leaking out of the tube through the hub. A pair of vascular interventional devices, at least one of which is constructed according to the invention, may be utilized to treat or study a cardiovascular condition, or to measure the blood pressure across a vascular segment.

Compositions that promote and / or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and / or maintain cardiovascular health through the prevention, stabilization, reversal and / or treatment of coronary artery disease and / or cerebrovascular disease. Such compositions may be used independently to promote and / or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and / or a health deteriorating condition.

Methods and devices for forming an anastomosis between hollow bodies utilizes magnetic force to couple anastomotic securing components and create a fluid-tight connection between the lumens of the hollow bodies. End-to-side, side-to-side and end-to-end anastomoses can be created without using suture or any other type of mechanical fasteners, although any such attachment means may be used in conjunction with the magnetic attachment. The securing components have magnetic, ferromagnetic or electromagnetic properties and may include one or more materials, for example, magnetic and nonmagnetic materials arranged in a laminated structure. The system of anastomotic securing components may be used in many different applications including the treatment of cardiovascular disease, peripheral vascular disease, forming AV shunts for dialysis patients, etc., and may be sized and configured for forming an anastomosis to a specific hollow body, for example, a coronary artery or the aorta.

The method of treating varicose veins and other vascular diseases provides sclerosant fluid through a catheter into the body vessel to be treated. The catheter has a lumen and a plurality of sidewall exits. The sclerosant fluid is provided under sufficient pressure so that it comes out of each exit as a jet of fluid with sufficient velocity to impinge on the vessel wall substantially orthogonal to the wall and thus minimize dilution of the sclerosant fluid and optimize coverage. A movable sheath on the catheter permits selecting a portion of the exits to be uncovered and thus create an infusion zone for the jets of sclerosant fluid which approximately match a desired treatment zone.

Methods and devices are provided for at least reducing the mineral content of a vascular calcified lesion, i.e. a calcified lesion present on the vascular tissue of a host. In the subject methods, the local environment of the lesion is maintained at a subphysiologic pH for a period of time sufficient for the mineral content of the lesion to be reduced, e.g. by flushing the lesion with a fluid capable of locally increasing the proton concentration in the region of the lesion. Also provided are systems and kits for practicing the subject methods. The subject methods and devices find particular use in the treatment of vascular diseases associated with the presence of calcified lesions on vascular tissue.

A method and system of performing an intravascular procedure at a treatment site in a vessel of a patient. A device creates a seal to prevent the flow of blood during the treatment of vascular disease. A seal may be formed between the distal inside diameter of a sheath or catheter such as a guide catheter as well as within a vessel, such as an artery or vein. An elongated device having a distal portion extending from the catheter and having a fluid impermeable membrane disposed about at least the distal end of the device is used to seal the vessel. The system includes a device to occlude blood flow and a distal protection device to filter or remove embolic debris.

A method of treating cardiovascular disease in a medical patient is provided. The method includes the steps of generating a sensor signal indicative of a fluid pressure within the left atrium of the patient's heart, and delivering an electrical stimulus to a location in the heart. The electrical stimulus is delivered based at least in part on the sensor signal. The method also includes the steps of generating a proccessor output indicative of a treatment to a signaling device. The processor output is based at least in part on the sensor signal. At least two treatment signals are provided to the medical patient. The treatment signals are distinguishable from one another by the patient, and are indicative of a therapeutic treatment. The treatment signals are based at least in part on the processor output.

Disclosed is a method for delivery of at least one therapeutic agent from an angioplasty balloon for treating vascular disease at a bifurcated vessel. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to a method of loading multiple beneficial agents onto the balloon surfaces

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and a therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and / or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

Optical sensor devices, image processing devices, methods and computer readable code computer-readable storage media for detecting biophysical parameters, chemical concentrations, chemical saturations, vital signs and physiological information such as a malignant condition are provided. In some embodiments, the optical sensor includes an array of photodetectors, where each photodetector is configured to detect a spectrum of light. In some embodiments, the image processing device receives a live still or video electronic image, or alternatively, the electronic image is provided from an electronic storage media. Exemplary physiological parameters include but are not limited to a pulse rate, a biophysical or physiological property of skin, a cardiovascular property, a property related to an organ such as the liver or the kidneys, and a temperature fluctuation. In some embodiments, the physiological parameter is indicative of a malady including but not limited to an autoimmune disease, a cancer, a nutritional deficiency, a malignant condition of bone marrow, a present of an infectious microbe such as a fungus, a present of hepatitis, and a cardiovascular disorder a pulmonary disorder. Exemplary chemical concentrations include but are not limited to a chemical saturation, a pH level, a pH level in blood vessels such as capillarys or in skin, a glucose level such as a blood glucose level, a urea nitrogen level such as a blood urea nitrogen level, a CO2 level such as a blood CO2 level or a CO2 saturation level, and an oxygen level such as a blood oxygen level or a blood oxygen saturation level. In some embodiments, the biophysical parameter, physiological parameter or chemical concentration is obtained from reflecting light from tissue from a mammalian subject. Alternatively one or more of these parameters are detected from a food item such as food tissue, a consumable beverage such as an alcoholic beverage, a dairy product, wine, a baked good, a fruit and a vegetable. Exemplary parameters related to food items include but are not limited to a parameter indicative of cooking or spoilage, a pH, a concentration of an antioxidant, and a concentration of an anti-inflammatory agent.

The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

The invention relates to methods, apparatus, articles-of-manufacture, and coded data signals for measuring cardiac output, limb blood flow, perfusion, blood pressure, artery elasticity, and cardiovascular deterioration and disease, including performing these measurements on a continuous heart beat-by-beat basis, for humans and animals. Unlike empirical methods of other noninvasive blood pressure concepts, the invention is grounded on scientifically appropriate hemodynamic principles that studies have validated as accurate, and is practical for wide clinical use. Devices constructed in accordance with the invention can be comfortably employed for numerous applications, including hospital monitoring, physician's office cardiovascular disease management and drug therapy monitoring, home monitoring, and athletic applications.The invention may be implemented in a variety of single or multi-sensor embodiments, such as: invasive pressure cannula sensor systems; non invasive pressure transducer arrays and piezo or other strain sensing materials that are placed against the skin above arteries; “upstream” pulsing-sensors (that apply single or multi-frequency vibrations that are measured “downstream” from the first placement location); other types of plethysmographic sensors; sonic / ultrasonic / Doppler sensors; MRI blood spin magnetizer / sensors; oxygen sensors; and electrocardiographic sensors, etc.

The invention discloses a covered stent, which comprises a support structure and a tectorial membrane unit, and is characterized in that: the tectorial membrane unit comprises an inner-layer tectorial membrane and an outer-layer tectorial membrane which coats the support structure; the outer-layer membrane coats on the outer side of the inner-layer tectorial membrane; the inner-layer tectorial membrane is a biological membrane with good blood compatibility, and the outer-layer tectorial membrane is a biological membrane which is easy to induce the formation of thrombus; the inner-layer tectorial membrane contacting blood has good blood compatibility, can effectively reduce the formation of the thrombus, and maintains normal blood flowing channels; and the outer-layer tectorial membrane can induce the formation of the thrombus in aneurysm or thrombus of bleeding parts, promotes the aneurysm to be quickly activated and reduced, reduces the mass effect in vivo, simultaneously effectively adheres endothelial cells, promotes differentiation and proliferation of cells, quickens the endothelialization of lesion parts of vessels, and can more effectively treat vascular diseases such as the aneurysm and the like.

Methods for treating vascular disease in humans and generating data representing treatment plans are disclosed. A first set of clinical vascular health data from a healthcare provider and representing a vascular health condition of a patient is received at a data center server that is communicatively coupled to a public data network. One or more vascular disease analysis algorithms are applied to the first set of vascular health data, to result in creating and storing an initial treatment plan for the patient. A second set of vascular health data is received from a monitoring device that is associated with the patient and that is communicatively coupled to the data network; the second set of data include Doppler monitor data obtained from the peripheral vascular system of the patient. One or more vascular analysis algorithms are applied to result in creating one or more supplementary treatment plans for the patient. At least one of the treatment plans includes a biofeedback interaction. The treatment plans are provided to the patient over the data network. The foregoing steps are iteratively repeated one or more times as determined by the physician and patient, resulting in improved vascular health.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

Methods for volumetric characterisation of perivascular adipose tissue use data collected by computed tomography (CT) scanning. The volumetric characterisation of perivascular adipose tissue allows the inflammatory status of underlying blood vessels to be established by CT scanning. This is of use in the diagnosis, prognosis and treatment of coronary and vascular disease.

Disclosed is a method for delivery of at least one therapeutic agent from an angioplasty balloon for treating vascular disease at a bifurcated vessel. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to a method of loading multiple beneficial agents onto the balloon surfaces

The invention discloses an in-vivo wireless communication device based on a vascular stent and a wireless communication system. The in-vivo wireless communication device comprises the vascular stent and a trigger circuit mounted on the vascular stent, the trigger circuit is used for acquiring health condition data related to vascular diseases and / or providing in-vivo therapy related to the vascular diseases, an output of the trigger circuit is fed to the vascular stent, the vascular stent serves as an antenna to transmit wireless signals outwards, and the vascular stent further serves as the antenna to receive wireless signals in vitro and transmit the wireless signals to the trigger circuit. A special antenna structure does not need to be arranged in a blood vessel, the in-vivo wireless communication device is small in size, and the blood vessel can be monitored and treated in real time at low cost.

A medical risk assessment method and computer program product resident on a computer or a hand-held device that allows a physician to determine the best strategy for primary and secondary cardiovascular disease prevention utilizing current guidelines and published medical literature. The computer program product evaluates a number of risk factors to determine specific recommendations for an individual patient, including Framingham risk scoring (FRS), pertinent medical history, individual lipid panel and advanced lipoprotein profiling, patient laboratory test results, and published literature on the effects of anti-lipid medicines on plasma concentration and / or composition of lipoprotein molecules and clinical outcomes. The risk assessment method establishes a cardiovascular treatment therapy strategy for a patient by determining a cardiac risk classification group, determining a cardiovascular treatment therapy based on the patient's lipoprotein profile and the patient's cardiac group risk classification, and presenting the cardiovascular treatment therapy for the patient to a medical practitioner on a patient evaluation display.

An anchor for a medical implant, a method of manufacturing an anchor, and a delivery system and method for delivering a medical implant, such as for monitoring physiological parameters, for example, for diagnosing and / or monitoring and / or treating cardiovascular diseases, such as CHF and CHD. The anchor includes a base member, arms, legs, features for securing the medical implant to the base member, and features for connecting the anchor to a connector. The anchor has a deployed configuration in which the arms radially project from a first end of the base member and the legs radially project from an opposite end of the base member. When deployed, the arms and legs terminate at extremities that are opposing but not aligned with each other.

A material in a flowable state is applied to the interstitial pores of a radially-expandable endovascular tubular braid structure to modify the tubular braid structure for use in the treatment of cardiovascular disease. The material is cured to form a membrane at least within the coated interstitial pores. A cardiovascular device, for use in a vascular lumen within a body for treatment of cardiovascular disease, includes a braided body with electroporation means for helping prevent restenosis in a cardiovascular lumen. A method for treating cardiovascular disease includes placing a radially expandable and collapsible medical device within a cardiovascular passageway, positioning it at a target site, and placing it in a radially expanded state. Restenosis at the target site is inhibited by a chosen one of electroporation and iontophoresis. The medical device is collapsed and is then removed from the passageway.

Imaging and therapy for the treatment of venous disease are integrated into the same device, such that there is a common user interface and / or display, which may be passive or interactive between image and therapy parameters.

The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates and / or cholesterol lowering agents or techniques, administered separately, in sequence or simultaneously. Cholesterol Metabolites (isoprenoids) are an integral component of the signaling pathway for Interleukin 6 mediated inflammation. Interleukin 6 inflammation is the common causative origin for Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism and isoprenoid depletion.